REPLIGEN CORP (RGEN) research
REPLIGEN CORP- Sector
- Life Sciences Tools & Services
- Last price
- $181.70
- As of
REPLIGEN CORP (RGEN): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-15.
As of . Source: SEC EDGAR filings for RGEN. Method and limitations.
Share the RGEN intelligence card
See the full RGEN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RGEN on one page. Preview it with sample data, then open it live with a free account.
Preview the RGEN dossierActive signals for RGEN
- highCONSENSUS_SELL
4 tracked funds reduced RGEN this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 71% of RGEN (2026Q2)
- mediumNEW_POSITION
MILLENNIUM MANAGEMENT LLC new position in RGEN
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +249% to RGEN (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +3201% to RGEN (2026Q2)
FREE, NO ACCOUNT
Every signal on RGEN, as it fires
You are seeing 5 of 14 signals recorded on RGEN since 2026-05-26.
The five above landed across 2 days. The other 9 were recorded on 3 other days. 8 of the 14 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in RGEN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 759916109 · 2026Q2 | $51.3M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 759916109 · 2026Q2 | $22.7M | 0.03% | , |
| D. E. Shaw & Co., Inc.CUSIP 759916109 · 2026Q2 | $11.4M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 759916109 · 2026Q2 | $1.4M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 759916AD1 · 2026Q2 | $929K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RGEN
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
RGEN against its peers
RGEN's operating margin of 7.5% ranks in the 65th percentile of 23 Life Sciences Tools & Services sub-industry peers, fiscal periods ending between 2025-10-31 and 2026-06-30.
| Metric | RGEN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 738M USD | 1.3B USD | 40 | 25 |
| Gross margin | n/a | 57.3% | n/a | 12 |
| Operating margin | 7.5% | -3.8% | 65 | 23 |
| Net margin | 6.6% | -3.6% | 60 | 25 |
| Return on equity | 2.3% | -5.0% | 58 | 24 |
| P / E | 211.3x | 39.5x | 96 | 11 |
Peers (25): TECH, AVTR, TXG, BRKR, CRL, TEM, MEDP, SHC, ADPT, ABCL, MTD, ILMN, WAT, IQV, A, FTRE, MRVI, DNA, DHR, PACB, CTKB, MLAB, OABI, TMO, CDXS. Fiscal periods ending between 2025-10-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (RGEN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more RGEN signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to RGENand get the insider, 13F, options, and confluence read in one view.